Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

What Was Tested

This registered phase 3 trial tested Tirzepatide for psoriasis and psoriatic arthritis.

Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.

It had two arms (groups): Ixekizumab (experimental) and Ixekizumab and Tirzepatide (experimental).

Ixekizumab administered subcutaneous (SC).

Ixekizumab concomitantly administered with tirzepatide SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 279 actual participants took part.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have signs and/or symptoms or documented diagnosis of Psoriatic Arthritis (PsA) for at least 6 months and currently fulfilling the classification of Psoriatic Arthritis (CASPAR) criteria. Have active PsA, defined as the presence of at least 3 of 68 tender joints and at least 3 of 66 swollen joints.

The full record lists 3 inclusion and 13 exclusion criteria; among the exclusions: have type 1 diabetes mellitus (t1dm); have insulin-treated type 2 diabetes mellitus (t2dm); have a prior or planned surgical treatment for obesity.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the psoriasis and psoriatic arthritis participants stayed in one arm throughout.

Being open-label, the Tirzepatide study did not mask who received what.

It started in 2024-09-24 with completion listed for 2025-11-18.

It ran at 86 sites in United States (81) and Puerto Rico (5).

Its stated primary purpose is treatment.

What Was Measured

It also tracked 3 secondary outcomes, for example Percentage of Participants Achieving ACR50.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide in 279 people with psoriasis and psoriatic arthritis.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, Psoriasis and psoriatic arthritis research.